Bayer pens $547M biobucks pact with biotech pushing the boundaries of noncoding RNA (August 28, 2024) | By James Waldron. Bayer executives were keen to stress to Fierce this summer that the German pharma giant’s appetite for dealmaking hasn’t been curbed by a groupwide restructuring. Its latest cancer-focused collaboration suggests Bayer has indeed retained a
Summary – Ross Youngs is the CEO & Founder of Biosortia Microbiomics, which provides small molecules and datasets from their deep access to unculturable microbes in microbiomes, a valuable, proven source for future therapeutics.
Otsuka Pharmaceutical to acquire Jnana Therapeutics in deal worth over $1.1bn The agreement includes a clinical-stage drug for the rare inherited metabolic disorder phenylketonuria (August 1, 2024) | By Emily Kimber. Jnana’s JNT-517 is an allosteric small molecule inhibitor of SLC6A19, a solute carrier that regulates amino acid reabsorption in the kidney, and has already
